HHLA2 and neoplasm: Although HHLA2 and FAP are expected to be associated with anti-tumor immune response, we could not verify whether the expression of HHLA2 and FAP affects the efficacy of immune checkpoint inhibitors, because only a few cases used immune checkpoint inhibitors in this study.